<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CYCLOPHOSPHAMIDEÂ - cyclophosphamideÂ tabletÂ </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>CYCLOPHOSPHAMIDE Tablets USP, 25 mg and 50 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c2abd0fa-33d9-4978-b190-fb14c5c0473a"></a><a name="section-1"></a><p></p>
<h1>Rx only</h1>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_edb8d4ca-5a7e-404e-bedc-c58afc22e73d"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Cyclophosphamide is a synthetic antineoplastic drug chemically related to the nitrogen mustards. Cyclophosphamide is a white crystalline powder with the molecular formula C<span class="Sub">7</span>H<span class="Sub">15</span>Cl<span class="Sub">2</span>N<span class="Sub">2</span>O<span class="Sub">2</span>P â€¢ H<span class="Sub">2</span>O and a molecular weight of 279.1. The chemical name for cyclophosphamide is 2<span class="Italics">H</span>-1,3,2-Oxazaphosphorin-2-amine, <span class="Italics">N,N</span>-bis(2-chloroethyl)tetrahydro-, 2-oxide, monohydrate, (Â±). Cyclophosphamide is soluble in water, saline, or ethanol and has the following structural formula:</p>
<div class="Figure"><img alt="chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15d30249-4714-4b13-b8ca-5dff38424282&amp;name=da1a5cfb-b6b0-4cd0-a002-1425ae11a7a7-03.jpg"></div>
<p>Each tablet for oral administration contains cyclophosphamide (anhydrous) 25 mg or 50 mg. In addition, each tablet contains the following inactive ingredients: acacia, FD&amp;C Blue No. 1, lactose monohydrate, magnesium stearate, and microcrystalline cellulose.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_fb081557-3e8b-41e1-9189-8073e354cbe0"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites by a mixed function microsomal oxidase system. These metabolites interfere with the growth of susceptible rapidly proliferating malignant cells. The mechanism of action is thought to involve cross-linking of tumor cell DNA.</p>
<p>Cyclophosphamide is well absorbed after oral administration with a bioavailability greater than 75%. The unchanged drug has an elimination half-life of 3 to 12 hours. It is eliminated primarily in the form of metabolites, but from 5% to 25% of the dose is excreted in urine as unchanged drug. Several cytotoxic and noncytotoxic metabolites have been identified in urine and in plasma. Concentrations of metabolites reach a maximum in plasma 2 to 3 hours after an intravenous dose. Plasma protein binding of unchanged drug is low but some metabolites are bound to an extent greater than 60%. It has not been demonstrated that any single metabolite is responsible for either the therapeutic or toxic effects of cyclophosphamide. Although elevated levels of metabolites of cyclophosphamide have been observed in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, increased clinical toxicity in such patients has not been demonstrated.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_fa462cc6-ba76-479a-ae9e-2c0e0f634881"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_90a4aab7-da56-44eb-851b-cdef8e2e293a"></a><a name="section-4.1"></a><p></p>
<h2>Malignant Diseases</h2>
<p class="First">Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment:</p>
<ol>
<li><span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">Malignant lymphomas</span> (Stages III and IV of the Ann Arbor staging system), Hodgkinâ€™s disease, <span class="product-label-link" type="condition" conceptid="4119130" conceptname="Malignant lymphoma - small lymphocytic">lymphocytic lymphoma</span> (nodular or diffuse), mixed-cell type <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, histiocytic <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, Burkittâ€™s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">Multiple myeloma</span>.</li>
<li><span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">Leukemias</span>: <span class="product-label-link" type="condition" conceptid="4082311" conceptname="B-cell chronic lymphocytic leukemia">Chronic lymphocytic leukemia</span>, <span class="product-label-link" type="condition" conceptid="134603" conceptname="Chronic myeloid leukemia">chronic granulocytic leukemia</span> (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, acute lymphoblastic (stem-cell) <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span> in children (cyclophosphamide given during remission is effective in prolonging its duration).</li>
<li><span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">Mycosis fungoides</span> (advanced disease).</li>
<li><span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">Neuroblastoma</span> (disseminated disease).</li>
<li>Adenocarcinoma of the ovary.</li>
<li>Retinoblastoma.</li>
<li>Carcinoma of the breast.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_88fc043d-989b-43a2-9fd4-450553401b01"></a><a name="section-4.2"></a><p></p>
<h2>Nonmalignant Disease</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_ac8443f3-34c5-40ee-b19b-d04c85af4c9c"></a><a name="section-4.2.1"></a><p></p>
<h3>Biopsy Proven â€œMinimal Changeâ€? <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Children:</h3>
<p class="First">Cyclophosphamide Tablets USP, 25 mg and 50 mg are useful in carefully selected cases of biopsy proven â€œminimal changeâ€? <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> in children but should not be used as primary therapy. In children whose disease fails to respond adequately to appropriate adrenocorticosteroid therapy or in whom the adrenocorticosteroid therapy produces or threatens to produce intolerable side effects, cyclophosphamide may induce a remission. Cyclophosphamide is not indicated for the <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span> in adults or for any other <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_4943329e-9b8e-49a9-a905-4599fbd7025a"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Continued use of cyclophosphamide is contraindicated in patients with severely depressed bone marrow function. Cyclophosphamide is contraindicated in patients who have demonstrated a previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to it (see <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a> and <a href="#i4i_precautions_id_d6b866a6-0037-4fba-8645-40b7ce78539e">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_dc9de4fb-ce09-4d5e-b707-3d6e7db4ebb8"></a><a name="section-6.1"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Second malignancies have developed in some patients treated with cyclophosphamide used alone or in association with other antineoplastic drugs and/or modalities. Most frequently, they have been urinary bladder, myeloproliferative, or lymphoproliferative malignancies. Second malignancies most frequently were detected in patients treated for primary myeloproliferative or lymphoproliferative malignancies or nonmalignant disease in which immune processes are believed to be involved pathologically. </p>
<p>In some cases, the second malignancy developed several years after cyclophosphamide treatment had been discontinued. In a single breast cancer trial utilizing two to four times the standard dose of cyclophosphamide in conjunction with doxorubicin a small number of cases of secondary <span class="product-label-link" type="condition" conceptid="140352" conceptname="Acute myeloid leukemia, disease">acute myeloid leukemia</span> occurred within two years of treatment initiation. Urinary bladder malignancies generally have occurred in patients who previously had <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. In patients treated with cyclophosphamide-containing regimens for a variety of <span class="product-label-link" type="condition" conceptid="4030314" conceptname="Neoplasm">solid tumors</span>, isolated case reports of secondary malignancies have been published. One case of carcinoma of the renal pelvis was reported in a patient receiving long-term cyclophosphamide therapy for cerebral <span class="product-label-link" type="condition" conceptid="4137275" conceptname="Vasculitis">vasculitis</span>. The possibility of cyclophosphamide-induced malignancy should be considered in any benefit-to-risk assessment for use of the drug.</p>
<p>Cyclophosphamide can cause fetal harm when administered to a pregnant woman and such abnormalities have been reported following cyclophosphamide therapy in pregnant women. Abnormalities were found in two infants and a six-month-old fetus born to women treated with cyclophosphamide. Ectrodactylia was found in two of the three cases. Normal infants have also been born to women treated with cyclophosphamide during pregnancy, including the first trimester. If this drug is used during pregnancy, or if the patient becomes pregnant while taking (receiving) this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.</p>
<p>Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> in both sexes. Development of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment. Cyclophosphamide-induced <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> may be irreversible in some patients.</p>
<p><span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span> associated with decreased estrogen and increased gonadotropin secretion develops in a significant proportion of women treated with cyclophosphamide. Affected patients generally resume regular menses within a few months after cessation of therapy. Girls treated with cyclophosphamide during prepubescence generally develop secondary sexual characteristics normally and have regular menses. Ovarian <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span> with apparently complete loss of germ cells after prolonged cyclophosphamide treatment in late prepubescence has been reported. Girls treated with cyclophosphamide during prepubescence subsequently have conceived.</p>
<p>Men treated with cyclophosphamide may develop <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> or <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> associated with increased gonadotropin but normal testosterone secretion. Sexual potency and libido are unimpaired in these patients. Boys treated with cyclophosphamide during prepubescence develop secondary sexual characteristics normally, but may have <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> or <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> and increased gonadotropin secretion. Some degree of <span class="product-label-link" type="condition" conceptid="438477" conceptname="Atrophy of testis">testicular atrophy</span> may occur. Cyclophosphamide-induced <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy. Men temporarily rendered sterile by cyclophosphamide have subsequently fathered normal children.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5def0242-80f4-48f7-b2e9-42a755ef6da4"></a><a name="section-6.2"></a><p></p>
<h2>Urinary System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">Hemorrhagic cystitis</span> may develop in patients treated with cyclophosphamide. Rarely, this condition can be severe and even fatal. <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">Fibrosis</span> of the urinary bladder, sometimes extensive, also may develop with or without accompanying <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>. Atypical urinary bladder epithelial cells may appear in the urine. These adverse effects appear to depend on the dose of cyclophosphamide and the duration of therapy. Such bladder injury is thought to be due to cyclophosphamide metabolites excreted in the urine. Forced fluid intake helps to assure an ample output of urine, necessitates frequent voiding, and reduces the time the drug remains in the bladder. This helps to prevent <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span>. <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span> usually resolves in a few days after cyclophosphamide treatment is stopped, but it may persist. Medical and/or surgical supportive treatment may be required, rarely, to treat protracted cases of severe <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>. It is usually necessary to discontinue cyclophosphamide therapy in instances of severe <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7f841d15-b0b7-4232-a674-13f54737091b"></a><a name="section-6.3"></a><p></p>
<h2>Cardiac Toxicity</h2>
<p class="First">Although a few instances of cardiac dysfunction have been reported following use of recommended doses of cyclophosphamide, no causal relationship has been established. Acute cardiac toxicity has been reported with doses as low as 2.4 g/m<span class="Sup">2</span> to as high as 26 g/m<span class="Sup">2</span>, usually as a portion of an intensive antineoplastic multi-drug regimen or in conjunction with transplantation procedures. In a few instances with high doses of cyclophosphamide, severe, and sometimes fatal, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> has occurred after the first cyclophosphamide dose. Histopathologic examination has primarily shown hemorrhagic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span>. <span class="product-label-link" type="condition" conceptid="258449" conceptname="Hemopericardium">Hemopericardium</span> has occurred secondary to hemorrhagic <span class="product-label-link" type="condition" conceptid="314383" conceptname="Myocarditis">myocarditis</span> and <span class="product-label-link" type="condition" conceptid="4354249" conceptname="Myocardial necrosis">myocardial necrosis</span>. <span class="product-label-link" type="condition" conceptid="4138837" conceptname="Pericarditis">Pericarditis</span> has been reported independent of any <span class="product-label-link" type="condition" conceptid="258449" conceptname="Hemopericardium">hemopericardium</span>. </p>
<p>No residual cardiac abnormalities, as evidenced by electrocardiogram or echocardiogram appear to be present in patients surviving episodes of apparent cardiac toxicity associated with high doses of cyclophosphamide. </p>
<p>Cyclophosphamide has been reported to potentiate doxorubicin-induced cardiotoxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95289bde-ea64-480b-ad5c-468d8dc3e4d3"></a><a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Treatment with cyclophosphamide may cause significant suppression of immune responses. Serious, sometimes fatal, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may develop in severely immunosuppressed patients. Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop viral, bacterial, fungal, protozoan, or <span class="product-label-link" type="condition" conceptid="194873" conceptname="Mixed intestinal helminthiasis">helminthic infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_748bc32e-e87d-4992-8c1f-01afbe143593"></a><a name="section-6.5"></a><p></p>
<h2>Other</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported; <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has also been reported in association with this event. Possible cross-sensitivity with other alkylating agents has been reported.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_d6b866a6-0037-4fba-8645-40b7ce78539e"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_10b9f06c-617b-4212-bdd7-f4ef730aaf9d"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Special attention to the possible development of toxicity should be exercised in patients being treated with cyclophosphamide if any of the following conditions are present:</p>
<ol>
<li><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></li>
<li><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></li>
<li>Tumor cell infiltration of bone marrow</li>
<li>Previous X-ray therapy</li>
<li>Previous therapy with other cytotoxic agents</li>
<li>Impaired hepatic function</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired renal function</span></li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="i4i_lab_tests_id_fbd0172f-08d3-450c-aff6-c6d37e368388"></a><a name="section-7.2"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">During treatment, the patientâ€™s hematologic profile (particularly <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and platelets) should be monitored regularly to determine the degree of hematopoietic suppression. Urine should also be examined regularly for red cells which may precede <span class="product-label-link" type="condition" conceptid="4227291" conceptname="Hemorrhagic cystitis">hemorrhagic cystitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_d9470157-0e00-4a71-befb-779faac0e210"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The rate of metabolism and the leukopenic activity of cyclophosphamide reportedly are increased by chronic administration of high doses of phenobarbital.</p>
<p>The physician should be alert for possible combined drug actions, desirable or undesirable, involving cyclophosphamide even though cyclophosphamide has been used successfully concurrently with other drugs, including other cytotoxic drugs.</p>
<p>Cyclophosphamide treatment, which causes a marked and persistent inhibition of <span class="product-label-link" type="condition" conceptid="4052720" conceptname="Acetylcholinesterase">cholinesterase</span> activity, potentiates the effect of succinylcholine chloride.</p>
<p>If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, the anesthesiologist should be alerted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7bb359ac-499f-4f72-8174-4f7ea39496a8"></a><a name="section-7.4"></a><p></p>
<h2>Adrenalectomy</h2>
<p class="First">Since cyclophosphamide has been reported to be more toxic in adrenalectomized dogs, adjustment of the doses of both replacement steroids and cyclophosphamide may be necessary for the adrenalectomized patient.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="i4i_abuse_id_ddc4cad6-2165-45cc-8456-ba1d23d0d8f4"></a><a name="section-7.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wound</span> Healing</h2>
<p class="First">Cyclophosphamide may interfere with normal <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_262d2482-bd12-4d0a-913c-5379c5feb3fe"></a><a name="section-7.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">See <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a>: <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_dc9de4fb-ce09-4d5e-b707-3d6e7db4ebb8">Carcinogenesis, Mutagenesis, and Impairment of Fertility</a>.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_83ae7e69-63e8-4428-846b-7dde13cab58d"></a><a name="section-7.7"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3e2532cc-4d0d-42a8-b723-ea34d606d133"></a><a name="section-7.7.1"></a><p></p>
<h3>Pregnancy Category D:</h3>
<p class="First">See <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_126f1ab1-1557-4381-86a7-87b394d21add"></a><a name="section-7.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Cyclophosphamide is excreted in breast milk. Because of the potential for serious adverse reactions and the potential for tumorigenicity shown for cyclophosphamide in humans, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_f4de6ed9-1af4-41a6-8ad7-9160664d5eee"></a><a name="section-7.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety profile of cyclophosphamide in pediatric patients is similar to that of the adult population (see <a href="#i4i_adverse_effects_id_16ca54b8-3566-404a-b7cd-8b288182c879">ADVERSE REACTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_e4e1ce37-163c-4e87-98d7-c9d63db2d718"></a><a name="section-7.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Insufficient data from clinical studies of cyclophospamide for <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">malignant lymphoma</span>, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>, <span class="product-label-link" type="condition" conceptid="4040380" conceptname="Mycosis fungoides">mycosis fungoides</span>, <span class="product-label-link" type="condition" conceptid="4333766" conceptname="Neuroblastoma">neuroblastoma</span>, retinoblastoma, and breast carcinoma are available for patients 65 years of age and older to determine whether they respond differently than younger patients. In two clinical trials in which cyclophosphamide was compared with paclitaxel, each in combination with cisplatin, for the treatment of advanced ovarian carcinoma, 154 (28%) of 552 patients who received cyclophosphamide plus cisplatin were 65 years or older. Subset analyses (&lt;65 versus &gt;65 years) from these trials, published reports of clinical trials of cyclophosphamide-containing regimens in breast cancer and non-Hodgkinâ€™s <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span>, and postmarketing experience suggest that elderly patients may be more susceptible to cyclophosphamide toxicities. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range and adjusting as necessary based on patient response (see <a href="#i4i_dosage_admin_id_2c4796c8-8aa4-4693-af42-3235b2a28cc2">DOSAGE AND ADMINISTRATION</a>: <a href="#i4i_section_id_45c5b5ca-02c5-48f4-844d-4b957b66a4ca">Treatment of Malignant Diseases</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_16ca54b8-3566-404a-b7cd-8b288182c879"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Information on adverse reactions associated with the use of cyclophosphamide is arranged according to body system affected or type of reaction. The adverse reactions are listed in order of decreasing incidence. The most serious adverse reactions are described in the <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a> section.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a2e2b7e6-307f-4056-bc7f-9eda7ab225da"></a><a name="section-8.1"></a><p></p>
<h2>Reproductive System</h2>
<p class="First">See <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a>: <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_dc9de4fb-ce09-4d5e-b707-3d6e7db4ebb8">Carcinogenesis, Mutagenesis, and Impairment of Fertility</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_eedd347b-a165-474a-b09f-feab3358e2aa"></a><a name="section-8.2"></a><p></p>
<h2>Digestive System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> commonly occur with cyclophosphamide therapy. <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span> and, less frequently, <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">abdominal discomfort</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> may occur. There are isolated reports of <span class="product-label-link" type="condition" conceptid="4216673" conceptname="Hemorrhagic colitis">hemorrhagic colitis</span>, oral <span class="product-label-link" type="condition" conceptid="442121" conceptname="Mucosal ulcer">mucosal ulceration</span> and <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span> occurring during therapy. These adverse drug effects generally remit when cyclophosphamide treatment is stopped.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_473f13c2-0c6a-4adb-9a8c-640ca1f3f471"></a><a name="section-8.3"></a><p></p>
<h2>Skin and Its Structures</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> occurs commonly in patients treated with cyclophosphamide. The hair can be expected to grow back after treatment with the drug or even during continued drug treatment, though it may be different in texture or color. <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin rash</span> occurs occasionally in patients receiving the drug. <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">Pigmentation</span> of the skin and changes in nails can occur. Very rare reports of <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> have been received during postmarketing surveillance; due to the nature of spontaneous adverse event reporting, a definitive causal relationship to cyclophosphamide has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_c7e022ae-5488-459f-afbe-f430b0fa866f"></a><a name="section-8.4"></a><p></p>
<h2>Hematopoietic System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> occurs in patients treated with cyclophosphamide, is related to the dose of drug, and can be used as a dosage guide. <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span> of less than 2000 cells/mm<span class="Sup">3</span> develops commonly in patients treated with an initial loading dose of the drug, and less frequently in patients maintained on smaller doses. The degree of <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> is particularly important because it correlates with a reduction in resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> without documented <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been reported in neutropenic patients. </p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> or <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span> develop occasionally in patients treated with cyclophosphamide. These hematologic effects usually can be reversed by reducing the drug dose or by interrupting treatment. Recovery from <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> usually begins in 7 to 10 days after cessation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7fe26bd7-007b-4471-84be-bed4e26fe07e"></a><a name="section-8.5"></a><p></p>
<h2>Urinary System</h2>
<p class="First">See <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a>: <a href="#i4i_section_id_5def0242-80f4-48f7-b2e9-42a755ef6da4">Urinary System</a> for information on <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">cystitis</span> and urinary <span class="product-label-link" type="condition" conceptid="4318846" conceptname="Fibrosis of urinary bladder">bladder fibrosis</span>.</p>
<p>Hemorrhagic <span class="product-label-link" type="condition" conceptid="4009173" conceptname="Ureteritis">ureteritis</span> and <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">renal tubular necrosis</span> have been reported to occur in patients treated with cyclophosphamide. Such lesions usually resolve following cessation of therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d5f154ba-c0ed-4d4b-9b86-6a778397d6f5"></a><a name="section-8.6"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">See <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a>: <a href="#i4i_section_id_95289bde-ea64-480b-ad5c-468d8dc3e4d3"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a> for information on reduced host resistance to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_fafd7b2c-4c2c-4a0c-9ac8-a24236c213e1"></a><a name="section-8.7"></a><p></p>
<h2>Carcinogenesis</h2>
<p class="First">See <a href="#i4i_warnings_id_5363072d-6cb1-430f-9c63-d2157370b4b5">WARNINGS</a>: <a href="#i4i_carcinogenesis_mutagenesis_fertility_id_dc9de4fb-ce09-4d5e-b707-3d6e7db4ebb8">Carcinogenesis, Mutagenesis, and Impairment of Fertility</a>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2a0f76dc-34bc-4957-b7d2-934796d70afb"></a><a name="section-8.8"></a><p></p>
<h2>Respiratory System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pneumonitis</span> has been reported as part of the postmarketing experience. <span class="product-label-link" type="condition" conceptid="4119786" conceptname="Interstitial lung disease">Interstitial pulmonary fibrosis</span> has been reported in patients receiving high doses of cyclophosphamide over a prolonged period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2aa69fff-7834-4432-b7cd-63065c0826e5"></a><a name="section-8.9"></a><p></p>
<h2>Other</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported; <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> has also been reported in association with this event. Possible cross-sensitivity with other alkylating agents has been reported. <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">SIADH</span> (syndrome of <span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate ADH secretion</span>) has been reported with the use of cyclophosphamide. <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span> and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span> have been reported as part of the postmarketing experience.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_a1422abc-ede6-41bf-97b5-d7ab22b01ca9"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">No specific antidote for cyclophosphamide is known. Overdosage should be managed with supportive measures, including appropriate treatment for any concurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, or cardiac toxicity should it occur.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_2c4796c8-8aa4-4693-af42-3235b2a28cc2"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_45c5b5ca-02c5-48f4-844d-4b957b66a4ca"></a><a name="section-10.1"></a><p></p>
<h2>Treatment of Malignant Diseases</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f655b002-9a89-4b8a-b7c8-88d810d861e2"></a><a name="section-10.1.1"></a><p></p>
<h3>Adults and Children:</h3>
<p class="First">Oral cyclophosphamide dosing is usually in the range of 1 to 5 mg/kg/day for both initial and maintenance dosing.</p>
<p>Many other regimens of intravenous and oral cyclophosphamide have been reported. Dosages must be adjusted in accord with evidence of antitumor activity and/or <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>. The total leukocyte count is a good, objective guide for regulating dosage. Transient decreases in the <span class="product-label-link" type="condition" conceptid="4298431" conceptname="White blood cell count">total white blood cell count</span> to 2000 cells/mm<span class="Sup">3</span> (following short courses) or more persistent reduction to 3000 cells/mm<span class="Sup">3</span> (with continuing therapy) are tolerated without serious risk of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> if there is no marked <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>.</p>
<p>When cyclophosphamide is included in combined cytotoxic regimens, it may be necessary to reduce the dose of cyclophosphamide, as well as that of the other drugs.</p>
<p>Cyclophosphamide and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system being used. Patients with compromised renal function may show some measurable changes in pharmacokinetic parameters of cyclophosphamide metabolism, but there is no consistent evidence indicating a need for cyclophosphamide dosage modification in patients with renal function impairment.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d80264b3-e1f2-45fd-ad84-6ef485e4725e"></a><a name="section-10.2"></a><p></p>
<h2>Treatment of Nonmalignant Diseases</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_3f655a91-5e01-4849-abf3-21a8cb218d2b"></a><a name="section-10.2.1"></a><p></p>
<h3>Biopsy Proven â€œMinimal Changeâ€? <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">Nephrotic Syndrome</span> in Children:</h3>
<p class="First">An oral dose of 2.5 to 3 mg/kg daily for a period of 60 to 90 days is recommended. In males, the incidence of <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span> and <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> increases if the duration of cyclophosphamide treatment exceeds 60 days. Treatment beyond 90 days increases the probability of <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span>. Adrenocorticosteroid therapy may be tapered and discontinued during the course of cyclophosphamide therapy (see <a href="#i4i_precautions_id_d6b866a6-0037-4fba-8645-40b7ce78539e">PRECAUTIONS</a>: <a href="#i4i_lab_tests_id_fbd0172f-08d3-450c-aff6-c6d37e368388">Laboratory Tests</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_67bcb82a-21cd-4de0-8054-f80fb11b61c2"></a><a name="section-10.3"></a><p></p>
<h2>Preparation and Handling of Solutions</h2>
<p class="First">Extemporaneous liquid preparations of cyclophosphamide for oral administration may be prepared by dissolving cyclophosphamide for injection in Aromatic Elixir, N.F. Such preparations should be stored under refrigeration in glass containers and used within 14 days.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_b1cedd59-6490-4db8-ac69-dc7825767fd2"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">Cyclophosphamide Tablets USP</span></p>
<p><span class="Bold">25 mg, light blue, round, unscored tablets</span></p>
<p><span class="Bold">(Identified 54 639)</span></p>
<p>NDC 54868-5218-0: Bottle of 100 tablets</p>
<p>NDC 54868-5218-1: Bottle of 10 tablets.</p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">50 mg, light blue, round, unscored tablets </span></p>
<p><span class="Bold">(Identified 54 980)</span></p>
<p>NDC 54868-5005-0: Bottle of 100 tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_dd09b7ca-aa92-4023-b8a5-da018131a6db"></a><a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Storage at or below 25Â°C (77Â°F) is recommended; this product will withstand brief exposure to temperatures up to 30Â°C (86Â°F) but should be protected from temperatures above 30Â°C (86Â°F).</p>
<p><span class="Bold">Procedures for proper handling and disposal</span> of anticancer drugs should be considered. Several guidelines on this subject have been published.<span class="Sup">1-8</span> There is no general agreement that all of the procedures recommended in the guidelines are necessary or appropriate.</p>
<p>To minimize the risk of dermal exposure, always wear impervious gloves when handling bottles containing cyclophosphamide tablets. This includes all handling activities in clinical settings, pharmacies, storerooms, and home healthcare settings, including during unpacking and inspection, transport within a facility, and dose preparation and administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b4db4b11-3d31-47c7-b390-e1efea2ac4ba"></a><a name="section-11.2"></a><p></p>
<h2>References</h2>
<ol>
<li>ONS Clinical Practice Committee. Cancer Chemotherapy Guidelines and Recommendations for Practice. Pittsburgh, PA: <span class="Italics">Oncology Nursing Society</span>; 1999:32-41.</li>
<li>Recommendations for the safe handling of parenteral antineoplastic drugs. Washington, DC: Division of Safety, National Institutes of Health; 1983. US Dept of Health and Human Services, Public Health Service publication NIH 83-2621.</li>
<li>AMA Council on Scientific Affairs. Guidelines for handling parenteral antineoplastics. <span class="Italics">JAMA</span>.1985; 253: 1590-1592.</li>
<li>National Study Commission on Cytotoxic Exposure. Recommendations for handling cytotoxic agents. 1987. Available from Louis P. Jeffrey, Chairman, National Study Commission on Cytotoxic Exposure. Massachusetts College of Pharmacy and Allied Health Sciences, 179 Longwood Avenue, Boston, MA 02115.</li>
<li>Clinical Oncological Society of Australia. Guidelines and recommendations for safe handling of antineoplastic agents. <span class="Italics">Med J Aust</span>.1983;1:426-428.</li>
<li>Jones RB, Frank R, <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> T. Safe handling of chemotherapeutic agents: a report from The Mount Sinai Medical Center. CA <span class="Italics">Cancer J Clin</span>.1983;33:258-263.</li>
<li>American Society of Hospital Pharmacists. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. <span class="Italics">Am J Hosp Pharm</span>.1990;47:1033-1049.</li>
<li>Controlling occupational exposure to hazardous drugs. (OSHA Work-Practice Guidelines.) <span class="Italics">Am J Health- Syst Pharm</span>.1996;53:1669-1685.</li>
</ol>
<p class="First"><span class="Bold">4047201//03</span></p>
<p><span class="Bold">Revised September 2007</span></p>
<p>Â© RLI, 2007</p>
<br><p><br></p>
<p><span class="Bold">Relabeling and Repackaging by:</span><br>Physicians Total Care, Inc.<br>Tulsa, OklahomaÂ Â Â Â Â Â Â  74146<br></p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2f87c7cf-dd39-4a90-b673-6f1e3c0f382c"></a><a name="section-12"></a><p></p>
<h1>Package Label - <span class="Bold">Cyclophosphamide Tablets USP</span>
</h1>
<p class="First"><span class="Bold">25 mg</span></p>
<p><span class="Bold">CYTOTOXIC AGENT</span></p>
<p>Rx Only</p>
<p><img alt="image of 25 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15d30249-4714-4b13-b8ca-5dff38424282&amp;name=5218.jpg"></p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">50 mg</span>Â </p>
<p><span class="Bold">CYTOTOXIC AGENT</span></p>
<p>Rx Only</p>
<div class="Figure"><img alt="image of 50 mg package label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15d30249-4714-4b13-b8ca-5dff38424282&amp;name=5005.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYCLOPHOSPHAMIDEÂ 		
					</strong><br><span class="contentTableReg">cyclophosphamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5218(NDC:0054-4129)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOPHOSPHAMIDE</strong> (CYCLOPHOSPHAMIDE) </td>
<td class="formItem">CYCLOPHOSPHAMIDE</td>
<td class="formItem">25Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;639</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5218-0</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5218-1</td>
<td class="formItem">10  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040032</td>
<td class="formItem">08/17/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CYCLOPHOSPHAMIDEÂ 		
					</strong><br><span class="contentTableReg">cyclophosphamide tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5005(NDC:0054-4130)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CYCLOPHOSPHAMIDE</strong> (CYCLOPHOSPHAMIDE) </td>
<td class="formItem">CYCLOPHOSPHAMIDE</td>
<td class="formItem">50Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ACACIA</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C BLUE NO. 1</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>LACTOSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (Light) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">11mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">54;980</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5005-0</td>
<td class="formItem">100  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040032</td>
<td class="formItem">08/17/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel, repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6f09d2d9-19e9-4068-9dce-33601a0425ec</div>
<div>Set id: 15d30249-4714-4b13-b8ca-5dff38424282</div>
<div>Version: 1</div>
<div>Effective Time: 20120123</div>
</div>
</div>Â <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
